196 related articles for article (PubMed ID: 28957841)
21. Acknowledging gray areas: 2015 vs. 2009 American Thyroid Association differentiated thyroid cancer guidelines on ablating putatively low-intermediate-risk patients.
Frangos S; Iakovou IP; Marlowe RJ; Eftychiou N; Patsali L; Vanezi A; Savva A; Mpalaris V; Giannoula EI
Eur J Nucl Med Mol Imaging; 2017 Feb; 44(2):185-189. PubMed ID: 27557846
[TBL] [Abstract][Full Text] [Related]
22. Implementing the Modified 2009 American Thyroid Association Risk Stratification System in Thyroid Cancer Patients with Low and Intermediate Risk of Recurrence.
Pitoia F; Jerkovich F; Urciuoli C; Schmidt A; Abelleira E; Bueno F; Cross G; Tuttle RM
Thyroid; 2015 Nov; 25(11):1235-42. PubMed ID: 26132983
[TBL] [Abstract][Full Text] [Related]
23. Can Age at Diagnosis and Sex Improve the Performance of the American Thyroid Association Risk Stratification System for Prediction of Structural Persistent and Recurrent Disease in Patients With Differentiated Thyroid Carcinoma? A Multicenter Study.
Zuhur SS; Aggul H; Çelik M; Avci U; Erol S; Kilinç F; Akbaba G; Cinar N; Tekin S; Sahin S; Bilen O; Elbuken G; Guldiken S; Kadioglu P; Bayraktaroglu T; Topcu B; Altuntas Y
Endocr Pract; 2022 Jan; 28(1):30-35. PubMed ID: 34508902
[TBL] [Abstract][Full Text] [Related]
24. Differentiated Thyroid Cancer in a Pediatric Population: Estimating the Risk of Recurrence and Evolution Over Time.
Damásio I; Dias D; Pinheiro S; Esteves S; Leite V; Santos R
Cureus; 2023 Jan; 15(1):e34313. PubMed ID: 36860222
[TBL] [Abstract][Full Text] [Related]
25. Prognostic Factors Improving ATA Risk System and Dynamic Risk Stratification in Low- and Intermediate-Risk DTC Patients.
Maino F; Botte M; Dalmiglio C; Valerio L; Brilli L; Trimarchi A; Mattii E; Cartocci A; Castagna MG
J Clin Endocrinol Metab; 2024 Feb; 109(3):722-729. PubMed ID: 37804529
[TBL] [Abstract][Full Text] [Related]
26. Patients with differentiated thyroid cancer who underwent radioiodine thyroid remnant ablation with low-activity ¹³¹I after either recombinant human TSH or thyroid hormone therapy withdrawal showed the same outcome after a 10-year follow-up.
Molinaro E; Giani C; Agate L; Biagini A; Pieruzzi L; Bianchi F; Brozzi F; Ceccarelli C; Viola D; Piaggi P; Vitti P; Pacini F; Elisei R
J Clin Endocrinol Metab; 2013 Jul; 98(7):2693-700. PubMed ID: 23626005
[TBL] [Abstract][Full Text] [Related]
27. Treatment outcomes in pediatric differentiated thyroid carcinoma.
Bhavani N; Bhadran K; Nair V; Menon UV; Pavithran PV; Menon AS; Abraham N; Pankaj A; Kumar H
J Pediatr Endocrinol Metab; 2018 Oct; 31(10):1117-1122. PubMed ID: 30157034
[TBL] [Abstract][Full Text] [Related]
28. [Risk of recurrence in differentiated thyroid cancer].
Domínguez JM; Martínez MT; Massardo JM; Muñoz S; Droppelmann N; González HE; Mosso L
Rev Med Chil; 2018 Mar; 146(3):282-289. PubMed ID: 29999097
[TBL] [Abstract][Full Text] [Related]
29. Clinical outcome of low-risk differentiated thyroid cancer patients after radioiodine remnant ablation and recombinant human thyroid-stimulating hormone preparation.
Vianello F; Mazzarotto R; Mian C; Lora O; Saladini G; Servodio O; Basso M; Pennelli G; Pelizzo MR; Sotti G
Clin Oncol (R Coll Radiol); 2012 Apr; 24(3):162-8. PubMed ID: 21411300
[TBL] [Abstract][Full Text] [Related]
30. Ongoing risk stratification for differentiated thyroid cancer (DTC) - stimulated serum thyroglobulin (Tg) before radioiodine (RAI) ablation, the most potent risk factor of cancer recurrence in M0 patients.
Krajewska J; Jarząb M; Czarniecka A; Roskosz J; Kukulska A; Handkiewicz-Junak D; Puch Z; Wygoda Z; Paliczka-Cieślik E; Kropińska A; Gubała E; Jurecka-Lubieniecka B; Jarząb B
Endokrynol Pol; 2016; 67(1):2-11. PubMed ID: 26884109
[TBL] [Abstract][Full Text] [Related]
31. Prognostic Factors for Early and Long-Term Remission in Pediatric Differentiated Thyroid Carcinoma: The Role of Sex, Age, Clinical Presentation, and the Newly Proposed American Thyroid Association Risk Stratification System.
Pires BP; Alves PA; Bordallo MA; Bulzico DA; Lopes FP; Farias T; Dias F; Lima RA; Santos Gisler IC; Coeli CM; Carvalhaes de Oliveira RV; Corbo R; Vaisman M; Vaisman F
Thyroid; 2016 Oct; 26(10):1480-1487. PubMed ID: 27540892
[TBL] [Abstract][Full Text] [Related]
32. Impact of early vs late postoperative radioiodine remnant ablation on final outcome in patients with low-risk well-differentiated thyroid cancer.
Tsirona S; Vlassopoulou V; Tzanela M; Rondogianni P; Ioannidis G; Vassilopoulos C; Botoula E; Trivizas P; Datseris I; Tsagarakis S
Clin Endocrinol (Oxf); 2014 Mar; 80(3):459-63. PubMed ID: 23895145
[TBL] [Abstract][Full Text] [Related]
33. Recombinant human thyroid stimulating hormone-assisted radioactive iodine remnant ablation in thyroid cancer patients at intermediate to high risk of recurrence.
Hugo J; Robenshtok E; Grewal R; Larson S; Tuttle RM
Thyroid; 2012 Oct; 22(10):1007-15. PubMed ID: 22873801
[TBL] [Abstract][Full Text] [Related]
34. The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma.
Tsang RW; Brierley JD; Simpson WJ; Panzarella T; Gospodarowicz MK; Sutcliffe SB
Cancer; 1998 Jan; 82(2):375-88. PubMed ID: 9445196
[TBL] [Abstract][Full Text] [Related]
35. Follow-up of differentiated thyroid carcinoma.
Pagano L; Klain M; Pulcrano M; Angellotti G; Pasano F; Salvatore M; Lombardi G; Biondi B
Minerva Endocrinol; 2004 Dec; 29(4):161-74. PubMed ID: 15765026
[TBL] [Abstract][Full Text] [Related]
36. [Management and dynamic risk stratification of differentiated thyroid cancer].
Huang YC; Li ZJ
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2019 May; 54(5):389-393. PubMed ID: 31137103
[TBL] [Abstract][Full Text] [Related]
37. Spontaneous remission in thyroid cancer patients after biochemical incomplete response to initial therapy.
Vaisman F; Momesso D; Bulzico DA; Pessoa CH; Dias F; Corbo R; Vaisman M; Tuttle RM
Clin Endocrinol (Oxf); 2012 Jul; 77(1):132-8. PubMed ID: 22248037
[TBL] [Abstract][Full Text] [Related]
38. Validation of dynamic risk stratification and impact of BRAF in risk assessment of thyroid cancer, a nation-wide multicenter study.
Pérez-Fernández L; Sastre J; Zafón C; Oleaga A; Castelblanco E; Capel I; Galofré JC; Guadalix-Iglesias S; De la Vieja A; Riesco-Eizaguirre G
Front Endocrinol (Lausanne); 2022; 13():1071775. PubMed ID: 36714606
[TBL] [Abstract][Full Text] [Related]
39. Treatment for microcarcinoma of the thyroid--clinical experience.
Küçük NO; Tari P; Tokmak E; Aras G
Clin Nucl Med; 2007 Apr; 32(4):279-81. PubMed ID: 17413573
[TBL] [Abstract][Full Text] [Related]
40. Neck Sonography and Suppressed Thyroglobulin Have High Sensitivity for Identifying Recurrent/Persistent Disease in Patients With Low-risk Thyroid Cancer Treated With Total Thyroidectomy and Radioactive Iodine Ablation, Making Stimulated Thyroglobulin Unnecessary.
Domínguez JM; Nilo F; Contreras T; Carmona R; Droppelmann N; González H; Iturrieta V; Tuttle RM
J Ultrasound Med; 2017 Nov; 36(11):2299-2307. PubMed ID: 28543974
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
